Evercore ISI Group has increased its price target for Quest Diagnostics (DGX) to $220, up from the previous $190. This adjustment reflects a significant 15.79% rise, signaling the firm's confidence in the company's growth prospects. Despite this optimistic revision, Evercore ISI maintained an "In-Line" rating for the stock. Countering this view, GuruFocus estimates a potential downside for DGX based on its GF Value fair value calculation. This divergence highlights a mixed outlook, where strong analyst confidence is tempered by valuation concerns. Investors will likely weigh both the upward target revision and the potential valuation risks when assessing DGX.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis